Jeannie Joughin
Direttore/Membro del Consiglio presso IMMURON LIMITED
Profilo
Jeannie Joughin is currently a Non-Executive Director at ImmVirX Pty Ltd., Immuron Ltd., and OneVentures Management Pty Ltd.
She previously held positions as a Non-Executive Director at Glutagen Sales Pty Ltd., Paranta Biosciences Ltd., and Paradigm Biopharmaceuticals Ltd.
She also served as a Vice President at CSL Behring LLC and Enable Injections, Inc., and as a Marketing Manager at Mayne Pharma Ltd.
Dr. Joughin has a background in Clinical Research at Bristol Myers Squibb Co. She obtained her undergraduate and doctorate degrees from Monash University in 1985 and 1988, respectively.
Posizioni attive di Jeannie Joughin
Società | Posizione | Inizio |
---|---|---|
IMMURON LIMITED | Direttore/Membro del Consiglio | 01/06/2024 |
OneVentures Management Pty Ltd.
OneVentures Management Pty Ltd. Investment ManagersFinance OneVentures Management Pty Ltd. (OneVentures) is a venture capital firm, a susbidiary of Andover Group Pty Ltd was founded in 2006 by Dr Michelle Deaker. The firm is headquartered in Australia. | Investitore di Private Equity | 01/08/2021 |
ImmVirX Pty Ltd.
ImmVirX Pty Ltd. Miscellaneous Commercial ServicesCommercial Services ImmVirX Pty Ltd. develops oncotic viral immunotherapy. The Australian company was founded in 2019 by Malcolm L. McColl and Darren Shafren. Malcolm L. McColl has been the CEO since 2019. | Direttore/Membro del Consiglio | - |
Precedenti posizioni note di Jeannie Joughin
Società | Posizione | Fine |
---|---|---|
Paranta Biosciences Ltd.
Paranta Biosciences Ltd. Pharmaceuticals: MajorHealth Technology Paranta Biosciences Ltd. engages in the research and development of novel biotherapeutic. t develops PB01 (recombinant human follistatin-288) for the treatment of fibrotic and inflammatory diseases. The company was founded in 2011 and is headquartered in Richmond, Australia. | Direttore/Membro del Consiglio | 01/06/2022 |
PARADIGM BIOPHARMACEUTICALS LIMITED | Direttore operativo | 30/06/2021 |
Glutagen Pty Ltd.
Glutagen Pty Ltd. Miscellaneous Commercial ServicesCommercial Services Glutagen Pty Ltd. develops enzyme therapies for the treatment of gluten intolerance and coeliac disease. The company has two products Glutazyme and Glutaren. The company was founded by Teodor Stelmasiak in 2001 and is headquartered in South Melbourne, Australia. | Direttore/Membro del Consiglio | 01/02/2020 |
Enable Injections, Inc.
Enable Injections, Inc. Medical SpecialtiesHealth Technology Enable Injections, Inc. develops wearable bolus injectors for investigational use in the pharmaceutical and biotechnology industries to deliver high viscosity, high volume payloads up to 20cc to the subcutaneous tissue. The company was founded by Michael D. Hooven in February 2010 and is headquartered in Cincinnati, OH. | Presidente | 01/01/2019 |
CSL Behring LLC
CSL Behring LLC BiotechnologyHealth Technology CSL Behring LLC researches, develops, manufactures, and markets biotherapies that are used to treat serious and rare conditions. It offers protein-based therapies in the areas of Bleeding Disorders, Fluid Replacement, Hereditary Angioedema, Immunoglobulin, Pulmonary, and Wound Healing Therapies. The company was founded in 2004 and is headquartered in King of Prussia, PA. | Presidente | 30/04/2015 |
Formazione di Jeannie Joughin
Monash University | Doctorate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Società quotate in Borsa | 2 |
---|---|
IMMURON LIMITED | Health Technology |
PARADIGM BIOPHARMACEUTICALS LIMITED | Health Technology |
Aziende private | 8 |
---|---|
CSL Behring LLC
CSL Behring LLC BiotechnologyHealth Technology CSL Behring LLC researches, develops, manufactures, and markets biotherapies that are used to treat serious and rare conditions. It offers protein-based therapies in the areas of Bleeding Disorders, Fluid Replacement, Hereditary Angioedema, Immunoglobulin, Pulmonary, and Wound Healing Therapies. The company was founded in 2004 and is headquartered in King of Prussia, PA. | Health Technology |
Mayne Pharma Ltd.
Mayne Pharma Ltd. Pharmaceuticals: OtherHealth Technology Mayne Pharma Ltd. manufactures pharmaceutical products. It distributes generic injectables for the oncology market. The company's competitors include Sandoz, Bedford Labs, and Ebewe. It was founded in November 2005 and is headquartered in Melbourne, Australia. | Health Technology |
Bristol Myers Squibb Co. /Australian Pharmaceutical Mfg Ops/ | Health Technology |
Glutagen Pty Ltd.
Glutagen Pty Ltd. Miscellaneous Commercial ServicesCommercial Services Glutagen Pty Ltd. develops enzyme therapies for the treatment of gluten intolerance and coeliac disease. The company has two products Glutazyme and Glutaren. The company was founded by Teodor Stelmasiak in 2001 and is headquartered in South Melbourne, Australia. | Commercial Services |
OneVentures Management Pty Ltd.
OneVentures Management Pty Ltd. Investment ManagersFinance OneVentures Management Pty Ltd. (OneVentures) is a venture capital firm, a susbidiary of Andover Group Pty Ltd was founded in 2006 by Dr Michelle Deaker. The firm is headquartered in Australia. | Finance |
Enable Injections, Inc.
Enable Injections, Inc. Medical SpecialtiesHealth Technology Enable Injections, Inc. develops wearable bolus injectors for investigational use in the pharmaceutical and biotechnology industries to deliver high viscosity, high volume payloads up to 20cc to the subcutaneous tissue. The company was founded by Michael D. Hooven in February 2010 and is headquartered in Cincinnati, OH. | Health Technology |
Paranta Biosciences Ltd.
Paranta Biosciences Ltd. Pharmaceuticals: MajorHealth Technology Paranta Biosciences Ltd. engages in the research and development of novel biotherapeutic. t develops PB01 (recombinant human follistatin-288) for the treatment of fibrotic and inflammatory diseases. The company was founded in 2011 and is headquartered in Richmond, Australia. | Health Technology |
ImmVirX Pty Ltd.
ImmVirX Pty Ltd. Miscellaneous Commercial ServicesCommercial Services ImmVirX Pty Ltd. develops oncotic viral immunotherapy. The Australian company was founded in 2019 by Malcolm L. McColl and Darren Shafren. Malcolm L. McColl has been the CEO since 2019. | Commercial Services |
- Borsa valori
- Insiders
- Jeannie Joughin